Cargando…

Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo

BACKGROUND: The MEK1/2 inhibitor selumetinib was recently approved for neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas, but outcomes could be improved and its pharmacodynamic evaluation in other relevant tissues is limited. The aim of this study was to assess selumetinib tissue pha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Osum, Sara H, Coutts, Alexander W, Duerre, Dylan J, Tschida, Barbara R, Kirstein, Mark N, Fisher, James, Bell, W Robert, Delpuech, Oona, Smith, Paul D, Widemann, Brigitte C, Moertel, Christopher L, Largaespada, David A, Watson, Adrienne L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Basic and Translational Investigations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8095338/ https://www.ncbi.nlm.nih.gov/pubmed/33978635 http://dx.doi.org/10.1093/noajnl/vdab020

Ejemplares similares

Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1
por: Isakson, Sara H., et al.
Publicado: (2018)

Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1
por: Osum, Sara H., et al.
Publicado: (2023)

Spontaneous and Engineered Large Animal Models of Neurofibromatosis Type 1
por: Osum, Sara H., et al.
Publicado: (2021)

Inhibition of YAP Sensitizes the Selumetinib Treatment for Neurofibromatosis Type 1 Related Plexiform Neurofibroma
por: Tian, Zhuowei, et al.
Publicado: (2023)

Case report of selumetinib as a novel therapy in a neurofibromatosis type 2-associated ependymoma
por: Blackwood, Nigel, et al.
Publicado: (2023)

Longitudinal phenotype development in a minipig model of neurofibromatosis type 1
por: Uthoff, Johanna, et al.
Publicado: (2020)

Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI
por: Beloueche-Babari, M, et al.
Publicado: (2013)

The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models
por: Holt, S V, et al.
Publicado: (2012)

Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells
por: Troiani, T, et al.
Publicado: (2012)

A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas
por: Eroglu, Z, et al.
Publicado: (2015)

Glucocorticoids and selumetinib are highly synergistic in RAS pathway-mutated childhood acute lymphoblastic leukemia through upregulation of BIM
por: Matheson, Elizabeth C., et al.
Publicado: (2019)

Selumetinib in Japanese pediatric patients with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas: An open-label, phase I study
por: Suenobu, Souichi, et al.
Publicado: (2023)

Identification of the Major Degradation Pathways of Selumetinib
por: Bouchema, Tahar Sif eddine, et al.
Publicado: (2022)

The Perceived Influence of Neurofibromatosis Type 1(NF1) on the Parents’ Relationship
por: Wiener, Lori, et al.
Publicado: (2023)

Acneiform rash as a side effect of selumetinib in a child with neurofibromatosis type 1 treated for inoperable plexiform neurofibromas: Good results with doxycycline
por: Volontè, Martina, et al.
Publicado: (2022)

Profile of selumetinib and its potential in the treatment of melanoma
por: Kim, Dae Won, et al.
Publicado: (2014)

Neuroprotective effect of selumetinib on acrolein-induced neurotoxicity
por: Huang, Hui-Ju, et al.
Publicado: (2021)

Effect of food on capsule and granule formulations of selumetinib
por: Cohen‐Rabbie, Sarit, et al.
Publicado: (2022)

Clinical impact of selumetinib on pediatric elephantiasis neuromatosa
por: Blegen, Kristina, et al.
Publicado: (2022)

Genomic Landscapes and Hallmarks of Mutant RAS in Human Cancers
por: Scharpf, Robert B., et al.
Publicado: (2022)

Overexpression of HGF/MET axis along with p53 inhibition induces de novo glioma formation in mice
por: Qin, Yuan, et al.
Publicado: (2020)

NFB-04. Evaluating focal areas of signal intensity (FASI) in children with neurofibromatosis type-1 (NF1) treated with selumetinib on PBTC-029B
por: Pillay Smiley, Natasha, et al.
Publicado: (2022)

Deconstructing Adipose Tissue Heterogeneity One Cell at a Time
por: Duerre, Dylan J., et al.
Publicado: (2022)

Population Pharmacokinetics of Selumetinib and Its Metabolite N‐desmethyl‐selumetinib in Adult Patients With Advanced Solid Tumors and Children With Low‐Grade Gliomas
por: Patel, YT, et al.
Publicado: (2017)

Impaired TNFα-induced A20 expression in E1A/Ras-transformed cells
por: Huang, H-L, et al.
Publicado: (2009)

H-Ras oncogene counteracts the growth-inhibitory effect of genistein in T24 bladder carcinoma cells
por: Li, C, et al.
Publicado: (2005)

The TAZ-CAMTA1 Fusion Protein Promotes Tumorigenesis via Connective Tissue Growth Factor and Ras–MAPK Signaling in Epithelioid Hemangioendothelioma
por: Ma, Shuang, et al.
Publicado: (2022)

CORRIGENDUM: Population Pharmacokinetics of Selumetinib and Its Metabolite N‐desmethyl‐selumetinib in Adult Patients With Advanced Solid Tumors and Children With Low‐Grade Gliomas
Publicado: (2017)

Validation of Bromodomain and Extraterminal proteins as therapeutic targets in neurofibromatosis type 2
por: Doherty, Joanne, et al.
Publicado: (2022)

RAS and beyond: the many faces of the neurofibromatosis type 1 protein
por: Anastasaki, Corina, et al.
Publicado: (2022)

Autonomic Cross-Innervation in Patients With Neurofibromatosis Type 2: Frey Syndrome and Unilateral Epiphora With Rhinorrhea
por: Evans, Erica, et al.
Publicado: (2019)

Evaluating Focal Areas of Signal Intensity (FASI) in Children with Neurofibromatosis Type-1 (NF1) Treated with Selumetinib on Pediatric Brain Tumor Consortium (PBTC)-029B
por: Pillay-Smiley, Natasha, et al.
Publicado: (2023)

Targeting RAS Mutant Colorectal Cancer with Dual Inhibition of MEK and CDK4/6
por: Sorokin, Alexey V., et al.
Publicado: (2022)

Selumetinib-based therapy in uveal melanoma patient-derived xenografts
por: Decaudin, Didier, et al.
Publicado: (2018)

Selumetinib - a potential small molecule inhibitor for osteoarthritis treatment
por: Zheng, Xiaohang, et al.
Publicado: (2022)

Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity
por: Watson, Adrienne L., et al.
Publicado: (2014)

Radiation Therapy in Management of Sporadic and Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors
por: Kahn, Jenna, et al.
Publicado: (2014)

Whole Body MRI at 3T with Quantitative Diffusion Weighted Imaging and Contrast-Enhanced Sequences for the Characterization of Peripheral Lesions in Patients with Neurofibromatosis Type 2 and Schwannomatosis
por: Fayad, Laura M., et al.
Publicado: (2013)

Growth dynamics of plexiform neurofibromas: a retrospective cohort study of 201 patients with neurofibromatosis 1
por: Nguyen, Rosa, et al.
Publicado: (2012)

RAS MAPK inhibitors deregulation in leukemia
por: Pasmant, Eric, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_eqeki0rs7pk9hebr3i32gpm7ov